Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, Fanella F, Pozzi G, Iannoni E, DIddio S (2011) Acetyl-l-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects
Most recently, results from the FLOW trial found that the GLP-1 Ozempic can slow the progression of kidney disease and reduce the risk of death from kidney or cardiovascular events
The potential cognitive effects of GLP-1 therapy appear most relevant for individuals with underlying metabolic dysfunction
NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis
What this means for research buyers If you are evaluating these compounds for research purposes: Read the original literature directly